Proton Magnetic Resonance Spectroscopy: Ex vivo study to investigate its prognostic role in colorectal cancer

Minicozzi, Annamaria; Mosconi, Elisa; Cordiano, Claudio; Rubello, Domenico; Marzola, Pasquina; Ferretti, Alice; Maffione, Anna Margherita; Sboarina, Andrea; Bencivenga, Maria; Boschi, Federico; Conti, Giamaica; Sbarbati, Andrea

doi:10.1016/j.biopha.2013.05.002

Cited by 5 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ex vivo MR spectroscopy: prediction of disease behaviour and survival A small number of studies have highlighted the potential of metabolic profile derived from ex vivo MRS tissue analysis in predicting disease behaviour 46 and survival outcomes. 47,48 The key findings are summarized in Table 5.…”

Section: Prognostic Valuementioning

confidence: 99%

“…MRS metabolic profiling can potentially predict patients at risk of tumour recurrence. 46 Minicozzi et al proposed a marker of malignancy (MRS-tm) based on the metabolic findings in a study by Chan et al 49 MRS-tm was defined as the ratio between the sum of the amplitudes of increasing components with peak between 3.0 and 3.8 ppm (including choline-containing compounds, taurine, scyllo-inositol and glycine) to the amplitude of the lipid methylene at 1.3 ppm. 4.7-T 1 H-MRS was performed on 29 surgical specimens.…”

Section: Prognostic Valuementioning

confidence: 99%

“…Ex vivo studies have shown higher levels of choline-containing compounds in colorectal tumour. 46,49 Ex vivo studies have demonstrated lower levels of cholinecontaining compounds and glycine, and higher taurine ratios in surgical specimens were associated with longer survival in patients with colorectal cancer. 47 The clinical MRS study found choline to be a potential biomarker of treatment response, with results showing a choline peak characteristic of rectal cancer at diagnosis and disappearance of this peak post CRT.…”

Section: Clinical Mr Spectroscopymentioning

confidence: 99%

See 2 more Smart Citations

Functional MRI for quantitative treatment response prediction in locally advanced rectal cancer

Pham

Liney

Wong

et al. 2017

BJR

View full text Add to dashboard Cite

Despite advances in multimodality treatment strategies for locally advanced rectal cancer and improvements in locoregional control, there is still a considerable variation in response to neoadjuvant chemoradiotherapy (CRT). Accurate prediction of response to neoadjuvant CRT would enable early stratification of management according to good responders and poor responders, in order to adapt treatment to improve therapeutic outcomes in rectal cancer. Clinical studies in diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI have shown promising results for the prediction of therapeutic response in rectal cancer. DWI allows for assessment of tumour cellularity. DCE-MRI enables evaluation of factors of the tumour microvascular environment and changes in perfusion in response to treatment. Studies have demonstrated that predictors of good response to CRT include lower tumour pre-CRT apparent diffusion coefficient (ADC), greater percentage increase in ADC during and post CRT, and higher pre-CRT K. However, the mean ADC and K values do not adequately reflect tumour heterogeneity. Multiparametric MRI using quantitative DWI and DCE-MRI in combination, and a histogram analysis technique can assess tumour heterogeneity and its response to treatment. This strategy has the potential to improve the accuracy of therapeutic response prediction in rectal cancer and warrants further investigation.

show abstract

Section: Prognostic Valuementioning

confidence: 99%

Section: Prognostic Valuementioning

confidence: 99%

Section: Clinical Mr Spectroscopymentioning

confidence: 99%

See 1 more Smart Citation

Functional MRI for quantitative treatment response prediction in locally advanced rectal cancer

Pham

Liney

Wong

et al. 2017

BJR

View full text Add to dashboard Cite

show abstract

“…Minicozzi et al observed in thirtysix head and neck cancer cases that cho/cr is signi cantly elevated in the group with poor response. 14 Fink et al found that multi-voxel MRS cho/cr peak-area shows great advantage for distinguishing glioma recurrence. 31 Negendank and colleagues conducted a co-operative study with 15 clinical research centers and con rmed that the cho was higher in glial tumors than in non-involved brain tissues.…”

Section: Discussionmentioning

confidence: 99%

“…13 MRS parameters have widely been shown to be capable of identifying the biology of tumor metabolism, and can monitor the treatment effect or tumor progression. 14,15 Our primary study have shown that cho/cr has been independently veri ed as useful predictors in the prognosis of NSCLC patients. 16 However, the occurrence of tumor is a comprehensive result of various systemic disorders, and its characteristics cannot be accurately predicted simply from one aspect.…”

mentioning

confidence: 99%

A Novel Score Combining Magnetic Resonance Spectroscopy Parameters and Systemic Immune-inflammation Index Improves Prognosis Prediction in Non-small-cell Lung Cancer With Brain Metastases

Guo¹,

Liu²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the significance of combination of the magnetic resonance spectroscopy (MRS) parameters and systemic immune-inflammation (SII) in patients with brain metastases (BM) from non-small-cell lung cancer (NSCLC) treated with stereotactic radiotherapy. Methods: 118 NSCLC patients with BM who treated with stereotactic radiotherapy were retrospectively enrolled into this study. All patients underwent MRS and blood samples test for SII analysis before the initiation of stereotactic radiotherapy. The correlation between the parameters of MRS and SII level were assessed using the spearman correlation coefficient. The cut-off values for the parameters of MRS, SII and clinical laboratory variables were defined by the receiver operating characteristic (ROC) curve analysis to quantify these predictive value. The prognostic factors of overall survival (OS) and progression-free survival (PFS) curves were assessed using Kaplan-Meier and Cox proportional hazards models.Results: The median follow-up time was 25 months (range, 12-49months). The optimal cutoff point for the cho/cr and SII were 1.50 and 480, respectively. The cho/cr was negatively correlated with SII (rs = 0.164, P = 0.075), but there was a trend. C-SII score was established by combining cho/cr and SII. Patients with both an elevated cho/cr (> 1.50) and an elevated SII (> 480) were given a C-SII score of 2, and patients with one or neither were given a C-SII score of 1 or 0, respectively. Kaplan–Meier analysis showed that the C-SII score of 2 was significantly linked with poor OS and PFS (P < 0.001, P < 0.001). In the Cox proportional hazards model, the C-SII score independently predicted OS [hazard ratio (HR), 1.749; 95% CI, 1.176-2.601; P = 0.006] and PFS (HR, 2.472; 95% CI, 1.624-3.763; P < 0.001). Conclusion: C-SII score was more accurate for predicting the clinical outcomes of NSCLC patients with BM who undergo stereotactic radiotherapy. The C-SII score, which was superior to either score alone, which could be used to identify for BM from NSCLC patients with poor outcomes.

show abstract

Closing the gap between in vivo and in vitro omics: using QA/QC to strengthen ex vivo NMR metabolomics

Maroli

Powers

2021

NMR in Biomedicine

View full text Add to dashboard Cite

Metabolomics aims to achieve a global quantitation of the pool of metabolites within a biological system. Importantly, metabolite concentrations serve as a sensitive marker of both genomic and phenotypic changes in response to both internal and external stimuli. NMR spectroscopy greatly aids in the understanding of both in vitro and in vivo physiological systems and in the identification of diagnostic and therapeutic biomarkers. Accordingly, NMR is widely utilized in metabolomics and fluxomics studies due to its limited requirements for sample preparation and chromatography, its non‐destructive and quantitative nature, its utility in the structural elucidation of unknown compounds, and, importantly, its versatility in the analysis of in vitro, in vivo, and ex vivo samples. This review provides an overview of the strengths and limitations of in vitro and in vivo experiments for translational research and discusses how ex vivo studies may overcome these weaknesses to facilitate the extrapolation of in vitro insights to an in vivo system. The application of NMR‐based metabolomics to ex vivo samples, tissues, and biofluids can provide essential information that is close to a living system (in vivo) with sensitivity and resolution comparable to those of in vitro studies. The success of this extrapolation process is critically dependent on high‐quality and reproducible data. Thus, the incorporation of robust quality assurance and quality control checks into the experimental design and execution of NMR‐based metabolomics experiments will ensure the successful extrapolation of ex vivo studies to benefit translational medicine.

show abstract

Proton Magnetic Resonance Spectroscopy: Ex vivo study to investigate its prognostic role in colorectal cancer

Cited by 5 publications

References 19 publications

Functional MRI for quantitative treatment response prediction in locally advanced rectal cancer

Functional MRI for quantitative treatment response prediction in locally advanced rectal cancer

A Novel Score Combining Magnetic Resonance Spectroscopy Parameters and Systemic Immune-inflammation Index Improves Prognosis Prediction in Non-small-cell Lung Cancer With Brain Metastases

Closing the gap between in vivo and in vitro omics: using QA/QC to strengthen ex vivo NMR metabolomics

Contact Info

Product

Resources

About